US Stem Cell Inc (USRM)

[zturk]

What's not to like here? This thing will fly. Just give it time.


U.S. Stem Cell, Inc. strives to provide accomplishments and value for both patients and shareholders. Below are highlights of financial results ending June 30, 2017.
Revenue up by 104% year-over-year for the quarter: from $678K in Q2 2016 to 1.38M in Q2 2017
Revenue up by 83% YTD: from $1.39M this time last year to $2.54M in Q2 2017
Margin increased from 65% to 71% quarter-to-quarter
Gross profit up by 122% (or $542K) year-over-year for the quarter: from $442K in Q2 2016 to $985K in Q2 2017
Gross profit up by 80% (or $796K) YTD: from $999K this time last year to $1.79M in Q2 2017
Income from operations increased from a loss of ($259K) in Q2 2016 to a gain of $142K in Q2 2017, a three-month comparison
Income from operations increased YTD from a loss of ($272K) in Q2 2016 to a gain of $100K in Q2 2017, a six-month comparison
Cash Flow is positive YTD at Q2 2017 at $785K compared to YTD Q2 2016 at ($165K), a six-month comparison
Working Capital Deficit down 6.9% from $5.8M in Q2 2016 to $5.4M in Q2 2017